Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxychloroquine plus lopinavir/ritonavir or atazanavir/ritonavir for hospitalized COVID-19
IRCT20100228003449N30Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Mar 2020
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of hydroxychloroquine, lopinavir, ritonavir and atazanavir in coronavirus pneumonia (2 arms), sponsored by Tehran University of Medical Sciences. Primary endpoints: Clinical response, Laboratory response and 1 more. Started Mar 2020; status: completed.
02
Drugs
hydroxychloroquinelopinavirritonaviratazanavir
03
Conditions
coronavirus pneumonia
Beyond the preview
Go deeper on IRCT20100228003449N30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20100228003449N30.